Time to move on

We have all lost a pile of money and so do we sell or hold? Either way the decision about TT-034 has been made (the right decision in my opinion), so there is no point in continuing to analyse the bejesus out of the situation.

Viral load reduction is important but, now that we have dropped the program, it is not as important as some may think. The import lessons we should have learnt are in relation to the use of the AAV8 vector, the levels of shrna’s and the variations between patent data. These data will help ensure that BB-HB-331 is designed correctly. This is what big pharma will be interested in. Viral load for HCV has nothing to do with what could be expected for HBV. Even if TT-034 was successful in the liver, it is quite possible that blood levels were still elevated because HCV replicates outside of the liver where TT-034 is ineffective. This was always a possibility and, if true, just means that the company belief that HCV does not replicated outside the liver was wrong. So TT-034 could have worked as designed and still not achieved a high percentage of viral reduction. The point is, we need to get the design right for BB-HB-331 rather than worry about the effect of TT-034 on viral load. We need to move on and look to our future.